Se prevé que el mercado de la salud animal alcance los 126.500,20 millones de dólares en 2028 desde los 87.547,03 millones de dólares estadounidenses en 2022; se estima que registrará una tasa compuesta anual del 6,2 % entre 2022 y 2028.
La prevención de enfermedades animales y el seguimiento del suministro de alimentos para animales son vitales para garantizar la seguridad del suministro de alimentos. La cría de ganado sano garantiza un suministro seguro de alimentos y mantiene estables los precios de venta. Las enfermedades zoonóticas pueden afectar negativamente a la salud pública, el comercio internacional y la estabilidad del sector agrícola, lo que resulta en una pérdida de millones de dólares debido a las interrupciones del comercio de ganado, los sacrificios de animales y los posteriores esfuerzos de eliminación de enfermedades. En noviembre de 2017, el virus del síndrome respiratorio y reproductivo porcino (PRRSV), que provoca la muerte de lechones, costó a los ganaderos estadounidenses 600 millones de dólares. Por lo tanto, es probable que animales libres de enfermedades y sanos resulten en suministros de alimentos más seguros, mayor productividad agrícola, menores impactos ambientales y menor uso de antibióticos.
Se espera que factores como la creciente incidencia de enfermedades zoonóticas, el aumento de la demanda de alimentos proteicos y las iniciativas de los gobiernos y las asociaciones de bienestar animal impulsen el crecimiento del mercado de salud animal durante el período de pronóstico. Sin embargo, es probable que el uso de medicamentos falsificados y la alta complejidad y costo de los procesos de desarrollo y aprobación de medicamentos para animales tengan un impacto negativo en el crecimiento del mercado de salud animal.
El mercado de salud animal está segmentado según el producto, el tipo de animal y la geografía. Por geografía, el mercado está ampliamente segmentado en América del Norte, Europa, Asia Pacífico, Medio Oriente y Asia. África y el Sur y el Sur. Centroamérica. El informe ofrece información y un análisis en profundidad del mercado, haciendo hincapié en parámetros como las tendencias del mercado, los avances tecnológicos y la dinámica del mercado, junto con el análisis del panorama competitivo de los principales actores del mercado del mundo.
Perspectivas estratégicas
regiones lucrativas para el mercado de salud animal
Perspectivas del mercado
Aumento de la adopción de mascotas como compañía
La adopción de mascotas es una tendencia importante en el mercado de la salud animal. Más del 67% de los hogares estadounidenses tienen mascotas, lo que suma casi 400 millones de mascotas, incluidos perros, gatos, caballos, pájaros y peces. Según la Sociedad Estadounidense para la Prevención de la Crueldad contra los Animales, ~6,5 millones de animales de compañía ingresan cada año a los refugios de animales de todo el país. El número de perros y gatos que ingresan a estos refugios anualmente ha disminuido desde ~7,2 millones en 2011. Esta disminución puede explicarse moderadamente por un aumento en el porcentaje de animales adoptados. Según la Federación Europea de la Industria de Alimentos para Mascotas (FEDIAF), los gatos siguen siendo las mascotas más populares en los hogares europeos con una población estable de 74,4 millones en la región. Además, la popularidad de los perros está creciendo, ya que en 2017 había 66,4 millones de perros de compañía en la UE (84,9 millones en Europa y Rusia), en comparación con 63,7 millones (82,2 millones) en 2016.
Los estadounidenses gastaron más de 75.500 millones de dólares en sus mascotas en 2016, con un gasto doméstico total promedio de dólares estadounidenses. 892 sobre alimento para mascotas, servicios veterinarios, suministros y otros servicios. Las mascotas mejoran la calidad de vida de sus dueños. salud y bienestar general, y puede ayudarles a vivir más tiempo. Las investigaciones muestran que los dueños de perros tienen un 36% menos de riesgo de morir por enfermedad cardiovascular y un 11% menos de riesgo de sufrir un ataque cardíaco. Por lo tanto, es probable que la tendencia hacia la adopción de mascotas impulse el crecimiento del mercado en el período de estudio.
Aumento de las actividades de I+D
Durante las últimas dos décadas, el costo y el tiempo de desarrollo de un producto de salud animal han aumentado en >100% y seis años, respectivamente. Según la Encuesta de Investigación y Desarrollo del Instituto de Salud Animal, las empresas de salud animal gastaron 663 millones de dólares en 2006 en I+D relacionados con nuevos productos potenciales, así como en investigación para mantener la larga vida útil de los productos ofrecidos. Esto constituye un aumento del 7% con respecto al gasto reportado en 2005. La investigación innovadora representa el 86% del gasto total en I+D, mientras que el 14% restante estuvo ocupado por la investigación necesaria para garantizar el rendimiento prolongado de los productos existentes.< /p>
Es probable que las inversiones de actores importantes aumenten aún más el crecimiento del mercado. Por ejemplo, Zoetis se centra en la innovación continua para desarrollar soluciones de salud animal que satisfagan las necesidades de los compradores. La I+D está en el centro de los esfuerzos de la empresa para proporcionar resultados de innovación que anticipen las necesidades futuras de los veterinarios y productores ganaderos en sus mercados locales. El 30 de enero de 2020, Zoetis y la Universidad Estatal de Colorado firmaron un acuerdo para establecer el Laboratorio de Investigación de Incubadoras Zoetis y comenzar una colaboración de investigación centrada en explorar el sistema inmunológico del ganado para apuntar a nuevas inmunoterapias.
< span>Información basada en productos
Según el producto, el mercado de salud animal se segmenta en prescripción y no prescripción. El segmento de prescripción tuvo una mayor participación del mercado en 2022. Se estima que el segmento de venta sin receta registrará una CAGR más alta del 7,0% en el mercado durante el período de pronóstico. El segmento de prescripción se subdivide en vacunas, productos farmacéuticos, aditivos alimentarios y diagnósticos. El segmento de venta sin receta se clasifica además en parasiticidas, productos de aseo y nutrición/suplementos.
Información basada en tipos de animales
Según el tipo de animal, el mercado de salud animal se segmenta en animales de producción y < un title="animal de compañía" href="https://www.theinsightpartners.com/reports/companion-animal-diagnostics-market" target="_blank" rel="noopener">animal de compañía. El segmento de animales de producción tuvo una mayor participación del mercado en 2022. Se estima que el segmento de animales de compañía registrará una CAGR más alta del 6,8 % en el mercado durante el período de pronóstico.
Mercado de salud animal, por tipo de animal: 2022 y 2028
Los lanzamientos de productos y las fusiones y adquisiciones son estrategias muy adoptadas por los actores que operan en el mercado mundial de sanidad animal. A continuación se enumeran algunos de los desarrollos de productos clave más recientes:
En febrero 2020, Vetoquinol SA anunció la adquisición de las familias de productos Profender y Drontal de Elanco Animal Health. También adquirirá propiedad intelectual, registros y otros derechos que actualmente pertenecen al negocio de salud animal de Bayer AG.
En enero de 2020, Nutreco NV anunció una inversión en una empresa holandesa, Kingfish Zeeland. La empresa pretende llevar suministros de pez rey de cola amarilla a los mercados estadounidense y europeo. La distribución se realizará a través de un sistema de acuicultura de recirculación patentado.
En marzo En 2020, Bayer AG anunció el lanzamiento de la iniciativa Care4Pigs; esto se lanzó en colaboración con el Centro de Educación sobre Bienestar de los Animales de Granja (FAWEC) y la Asociación Coreana de Veterinarios Porcinos (KASV). En el marco de la colaboración, se otorgaron 10.000 EUR para apoyar la innovación destinada a mejorar el bienestar de los cerdos.
En febrero de 2020, Zoetis recibió la aprobación de la FDA para Simparica Trio, una nueva combinación preventiva de parásitos para perros. Es la primera tableta masticable mensual lanzada en los EE. UU. que brinda protección todo en uno contra la dirofilariosis, las garrapatas, las pulgas, los ascárides y los anquilostomas en los perros.
Perfiles de la empresa
- Merck & Co., Inc
- Boehringer Ingelheim International GmbH
- Ceva Santé Animale
- Cargill, Incorporated
- Zoetis Inc.
- Bayer AG
- Vetoquinol SA
- Nutreco NV
- Virbac
- Elanco
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Similar to human animals are also affected by various diseases, which result in behavioral changes, uneasy conditions, and less production, among others. Several types of diseases can adversely affect animal health, and the diseases may include zoonotic diseases, transboundary diseases, insect-borne diseases, and diseases of production and hygiene, among others. On the other hand, animals assist in building economies through various businesses. For instance, production or livestock animals guarantee a safe supply of food and keep selling prices stable, which in return helps in earning a good income. Therefore, it is essential to maintain good animal health. Animals can be kept healthy by taking measures for their health. Animal owners should regularly take their animals to veterans to diagnose problems related to their health. The animal should be regularly given vaccines to prevent diseases. Thus, such measures assist in marinating good animal health.
The growth of animal health market is driven by some key driving factors such as increasing incidences of zoonotic diseases, rise in demand for proteinaceous food, and initiatives by governments and animal welfare associations. However the use of counterfeit medicines, and high complexity and cost of animal drug development and approval processes are likely to restraint the market growth during the forecast period.
Developing a drug for animals is much complicated and is a bit expensive. The stringent government regulations for drug approvals are the biggest hurdles in the animal health industry. The drug development process can take up to 5–7 years and cost more than US$ 10 million before entering the stage of approval. In addition, animal medicines remain heavily regulated and are subjected to strict laws that protect animals and humans, as well as the environment. Thus, drug development for animals is quite costlier, and sometimes it may become a restraint for the animal health market.
The List of Companies - Animal Health Market
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Ceva Santé Animale
- Cargill, Incorporated
- Zoetis Inc.
- Bayer AG
- Vetoquinol SA
- Nutreco N.V
- Virbac
- Elanco
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Apr 2024
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Apr 2024
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2024
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Apr 2024
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Apr 2024
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Apr 2024
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Apr 2024
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)